Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical versus intravenous oxytocin for blood loss reduction during myomectomy
IRCT20241103063575N1Phase 2Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, single-blind trial of oxytocin in Fibromyoma (LM) (2 arms), sponsored by Alborz University of Medical Sciences. Primary endpoint: Amount of bleeding during myomectomy. Started Jan 2025; status: completed.
02
Drugs
oxytocin
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on IRCT20241103063575N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241103063575N1.